Zoladex (goserelin) 3.6mg Implant Recalled, Class II, Temperature Abuse
TerSera Therapeutics initiated a Class II recall of Zoladex (goserelin) 3.6 mg implants on Aug 31, 2026 due to temperature abuse during shipping.
Read Full ArticleAll News
Exenatide Prefilled Pens Recalled (Class II) for Delivery Defect
Amneal Pharmaceuticals of New York initiated a Class II recall of Exenatide Injection pens on Aug 28, 2026, citing possible empty pens.
Acthar Gel (Corticotropin) Recalled: Class II, Particulate Matter Found
Mallinckrodt initiated a Class II recall of Acthar Gel on Aug 6, 2026, citing particulate matter including glass and stopper pieces in vials.
Vasopressin Injection Recalled by Baxter Over CGMP Deviations
Baxter Healthcare recalled Vasopressin in 0.9% Sodium Chloride Injection on Aug 6, 2026, a Class II recall citing CGMP deviations. Status is ongoing.
Baxter Recalls Vasopressin Injection Over CGMP Deviations
Baxter Healthcare initiated a Class II recall of Vasopressin in 0.9% Sodium Chloride Injection on Aug 6, 2026, citing CGMP deviations. Recall is ongoing.
Glucagon Emergency Kit Recalled (Class II) Over Stability Test Failure
Lupin Pharmaceuticals recalled Glucagon Emergency Kit vials as a Class II action after an out-of-specification stability test result, effective June 23, 2026.
Liraglutide Injection Recalled (Class II) Over Particulate Matter
Lupin Pharmaceuticals initiated a Class II recall of Liraglutide Injection on April 24, 2026, citing a white thread-like particulate found in cartridges.
Octreotide Acetate Injectable Suspension Recalled (Class II)
Teva initiated a Class II recall of Octreotide Acetate for Injectable Suspension on April 24, 2026, citing lack of assurance of sterility.
Desmopressin Nasal Spray Recalled (Class II) Over Bottle Cap Defect
Apotex Corp. initiated a Class II recall of Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL on April 8, 2026, citing defective bottle cap liners.
Octreotide Acetate Injection Recalled (Class II) Over Sterility Concerns
Teva Pharmaceuticals initiated a Class II recall of Octreotide Acetate for Injectable Suspension on March 17, 2026, citing sterility assurance issues.
Octreotide Acetate Injectable Suspension Recalled (Class II)
Teva Pharmaceuticals initiated a Class II recall of Octreotide Acetate for Injectable Suspension on March 17, 2026, citing lack of sterility assurance.
Octreotide Acetate Injectable Suspension Recalled (Class II) by Teva
Teva Pharmaceuticals initiated a Class II recall of Octreotide Acetate for Injectable Suspension on March 17, 2026, citing lack of sterility assurance.
Lanreotide Injection Recalled (Class II) Over Sterility Assurance Concern
Cipla USA recalled Lanreotide Injection 120 mg/0.5 mL as a Class II action, citing lack of assurance of sterility from an FDA site observation.
Lanreotide Acetate Injection Recalled by Cipla USA (Class II)
Cipla USA initiated a Class II recall of Lanreotide Acetate Injection on March 13, 2026, citing lack of assurance of sterility at a contract site.
Cetrorelix Acetate Injection Kit Recalled (Class II) Over Needle Defect
Meitheal Pharmaceuticals initiated a Class II recall of Cetrorelix Acetate for Injection Kits on Feb 9, 2026, citing missing or duplicated needles in the kits.
Lanreotide Injection Recalled (Class II) Over Particulate Matter
Cipla USA initiated a Class II recall of Lanreotide Injection 120 mg/0.5 mL on Jan 2, 2026, citing presence of particulate matter. Recall is ongoing.
Ganirelix Acetate Injection Recalled: Class II, Impurity Issue
Lupin Pharmaceuticals initiated a Class II recall of Ganirelix Acetate Injection on Nov 13, 2025 due to an out of specification impurity result.
Vasopressin Injection Recalled by American Regent (Class II)
American Regent recalled Vasopressin Injection, USP in a Class II action initiated May 13, 2024, citing subpotency and impurity test results.
HUMALOG (Insulin Lispro) Recalled in Class II FDA Action
Eli Lilly & Company initiated a Class II recall of HUMALOG U-100 insulin lispro injection on March 12, 2024, citing CGMP deviations. Status: Completed.
Terlivaz (Terlipressin) Recalled in Class II Action Over Temperature Excursion
Mallinckrodt initiated a Class II recall of Terlivaz (terlipressin) on Feb 6, 2024, citing a temperature excursion from a shipping delay to the distributor.
Acthar Gel (Corticotropin) Class II Recall Over Temperature Excursion
Mallinckrodt Hospital Products initiated a Class II recall of Acthar Gel on Feb 6, 2024 due to a shipping temperature excursion, a cGMP deviation.